Copy
CANCER CLINICAL TRIALS NEWSLETTER

This is a prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with pembrolizumab or TIL LN-145/LN-145-S1 as a single therapy. The adoptive cell transfer therapy used in this study involves patients receiving a nonmyeloablative (NMA) lymphodepletion regimen, followed by infusion of autologous TIL followed by the administration of a regimen of IL-2. Patients in Cohorts 1A, Cohort 2A, and Cohort 3A will receive TIL plus pembrolizumab. Patients in Cohorts 1B and Cohort 3B will receive TIL as a single therapy. 


(IOV-COM-202, IRB 2019-1110)

INCB57643-103
IRB 2020-0555
A Phase I, Open-Label, Safety and Tolerability Study of INCB057643 in participants With Myelofibrosis
UCCC-HN-19-03
IRB 2019-1161
An Open-label, Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
Click Here to Download All Cancer Trials Open to Accrual
Questions?  Please call us at 513-584-7698, or email us!

Our phone-based research recruitment app has features updates and a new look! It is available to all UC Cancer Center members and outside colleagues to aid in patient recruitment into cancer and other research studies.

Have you ever wanted to discuss research participation with a patient, but didn’t have the necessary study information at your fingertips to do so? The UC Cancer Center has partnered with High Enroll, LLC, to provide a valuable tool to solve this problem. This new phone-based application is available for all UC and non-UC referring providers. The new app allows for the entire recruiting portfolio of UC Cancer Center studies to always be updated by the research team. For each study, a summary, inclusion and exclusion criteria, other pertinent study information, and a “one-touch” contact button for the primary research coordinator are included

It takes only seconds to get the new app. On your phone, simply go to https://ctra.highenroll.org. Add the app to your home screen for quick and easy use.  Please delete all other prior versions of the app. 

If you have any questions, please research out to your UC Cancer Center research team or High Enroll members, Dr. Dylan Steen @ 908-208-6927, dlsteen@highenroll.org or Ginger Conway @859-992-5339, gaconway@highenroll.org.

 

 Thanks,

Dylan and Ginger

https://uc.us20.list-manage.com/track/open.php?u=6e0c6353f4d0cff892fa85067&id=17c04815d2&e=e50cd33d0c

UC studies tobacco use, cancer connection

University of Cincinnati researchers have found that tobacco use changes metabolism of kidney cancer, which may lead to targeted treatments. The data show that tumors from longtime smokers represent a separate metabolic subtype of kidney cancer with different weaknesses and which could require a dedicated treatment strategy. 

Click Here to Visit the UC Newsroom
Facebook
Twitter
UC Health Office of Clinical Research
Email Us
Check out our YouTube chanel!
CANCER CLINICAL TRIALS NEWSLETTER
Questions?  Please call us at 513-584-7698, or email us!
Facebook
Twitter
UC Health Office of Clinical Research
Email Us
Check out our YouTube chanel!
Copyright © 2019, All rights reserved.

UC Cancer Center Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:
marcumma@ucmail.uc.edu






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
UCCI Clinical Trials · 200 Albert Sabin Way Ste 4002A · Ml 0502 · Cincinnati, OH 45267-0502 · USA